Although numerous studies have shown that visfatin is linked to several cancers, its prognostic value is still unclear. This first comprehensive meta-analysis was performed to evaluate the prognostic effect of visfatin in cancer patients. A systematic search was conducted for relevant studies in health-related electronic databases up to May 2019. The pooled hazard ratios (HRs) and ORs with 95% confidence intervals (CIs) for total and stratified analyses were calculated to demonstrate the prognostic value of visfatin expression level in cancer patients. Heterogeneity and publication bias were also investigated. A total of 14 eligible studies with 1616 patients were included in the current meta-analysis. Pooling results revealed that, high visfatin expression was significantly associated with poorer overall survival (OS) (HR = 2.43, 95% CI 1.64-3.62, P < 0.001). Elevated visfatin level was also correlated with positive lymph node metastasis (OR = 2.45, 95% CI 1.43-4.17, P ≤ 0.001), positive distance metastasis (OR = 2014, 95% CI 1.25-3.69, P ≤ 0.001), advanced tumor stage (OR = 3.01, 95% CI 1.91-7.72, P ≤ 0.001), and larger tumor size (OR = 1.99, 95% CI 1.49-2.69, P ≤ 0.001). Our meta-results indicates that altered visfatin expression is a potential indicator of poor clinical outcomes in tumor patients, suggesting that high visfatin expression may serve as a potential biomarker of poor prognosis and metastasis in cancers.

中文翻译：

---

visfatin 在各种人类恶性肿瘤中的预后价值：系统评价和荟萃分析

尽管大量研究表明内脂素与多种癌症有关，但其预后价值仍不清楚。进行首次综合荟萃分析以评估内脂素对癌症患者的预后影响。对截至 2019 年 5 月的健康相关电子数据库中的相关研究进行了系统搜索。 计算了总体和分层分析的汇总风险比 (HR) 和具有 95% 置信区间 (CI) 的 OR，以证明 visfatin 的预后价值癌症患者中的表达水平。还研究了异质性和发表偏倚。目前的荟萃分析共纳入了 14 项符合条件的研究，涉及 1616 名患者。汇总结果显示，高内脂素表达与较差的总生存期（OS）显着相关（HR = 2.43，95% CI 1.64-3.62，P < 0.001)。内脂素水平升高还与阳性淋巴结转移（OR = 2.45，95% CI 1.43-4.17，P ≤ 0.001），阳性远处转移（OR = 2014，95% CI 1.25-3.69，P ≤ 0.001），晚期肿瘤相关分期（OR = 3.01，95% CI 1.91-7.72，P ≤ 0.001）和更大的肿瘤大小（OR = 1.99，95% CI 1.49-2.69，P ≤ 0.001）。我们的荟萃结果表明，内脂素表达的改变是肿瘤患者临床预后不良的潜在指标，表明内脂素的高表达可能是癌症预后不良和转移的潜在生物标志物。和更大的肿瘤大小（OR = 1.99，95% CI 1.49-2.69，P ≤ 0.001）。我们的荟萃结果表明，内脂素表达的改变是肿瘤患者临床预后不良的潜在指标，表明内脂素的高表达可能是癌症预后不良和转移的潜在生物标志物。和更大的肿瘤大小（OR = 1.99，95% CI 1.49-2.69，P ≤ 0.001）。我们的荟萃结果表明，内脂素表达的改变是肿瘤患者临床预后不良的潜在指标，表明内脂素的高表达可能是癌症预后不良和转移的潜在生物标志物。